PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

A.D.A.M. Medical Encyclopedia. Atlanta (GA): A.D.A.M.; 2011.

A.D.A.M. Medical Encyclopedia.

Postherpetic neuralgia

Last reviewed: June 28, 2011.

Postherpetic neuralgia is pain that lasts for more than a month after a shingles infection occurred. The pain may last for months or years.

Causes, incidence, and risk factors

Postherpetic neuralgia occurs when the nerves have been damaged after an outbreak of shingles. Shingles is caused by the varicella zoster virus, the same virus that causes chickenpox.

Postherpetic neuralgia is more likely to occur in people over age 60.

Symptoms

The main symptom is pain in the area where shingles once occurred.

  • The pain can range from mild to very severe. It may continue, or come and go.

  • The pain is described as a deep aching, burning, stabbing, or feeling like an electric shock.

  • People with this pain are very sensitive to touch or temperature changes.

The pain lasts for months or sometimes years after the shingles infection.

Treatment

Anticonvulsant drugs, usually used for seizures, may help with the pain of damaged nerves. Gabapentin and pregabalin are the ones most often used to treat postherpetic neuralgia.

Skin patches with lidocaine (a numbing medicine) may also be prescribed to relieve some of the pain for a period of time.

Pain medications are often needed. Sometimes acetaminophen or NSAIDs such as ibuprofen are enough. Many patients will need stronger, prescription drugs such as codeine, hydrocodone, or oxycodone.

Drugs used to treat depression (antidepressants) may also help reduce pain, as well as help with sleep.

Electrical nerve stimulators may be used for severe, long-term cases of postherpetic neuralgia.

Some people may need help from a pain specialist.

Prevention

A herpes zoster vaccine is available. It is different from the chickenpox vaccine that children or young adults may receive. Adults over age 50 should get the herpes zoster vaccine as part of their routine medical care.

A single shot of the vaccine can cut the risk of getting shingles by about half. It may also help prevent postherpetic neuralgia and ophthalmic herpes.

Because the vaccine contains a live virus, it cannot be given to people who have a weak immune system.

References

  1. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2011. Ann Intern Med. 2011;154:168-173.
  2. Chen N, Li Q, Zhang Y, Zhou M, Zhou D, He L. Vaccination for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2011 Mar 16;3:CD007795. [PubMed: 19370655]
  3. Wilson IF. Herpes zoster. Ann Intern Med. 2011;154:ITC31-15.

Review Date: 6/28/2011.

Reviewed by: Ari S. Eckman, MD, Chief, Division of Endocrinology, Diabetes and Metabolism, Trinitas Regional Medical Center, Elizabeth, NJ. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.

A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only — they do not constitute endorsementscof those other sites. © 1997–2011 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

What works?

  • Topical lidocaine (a local anaesthetic) for the treatment of postherpetic neuralgia (nerve pain) Topical lidocaine (a local anaesthetic) for the treatment of postherpetic neuralgia (nerve pain)
    Topical lidocaine may benefit some patients on an individual basis though there is stronger evidence for the use of other drugs. Postherpetic neuralgia is a long‐lasting pain disorder that causes pain from stimuli that are not normally painful. Local anaesthetics (such as lidocaine) can reduce the sensation of pain that is transmitted through nerves, and allow pain relief in patients with postherpetic neuralgia. This review found three small studies involving 182 topical lidocaine treated participants and 132 control participants using lidocaine for patients with postherpetic neuralgia. Two studies provided data on pain relief amongst patients with postherpetic neuralgia, and they showed some improvement in pain when topical lidocaine was compared to a placebo. No comparison was made with other medications that are in current use for the treatment of postherpetic neuralgia. The side effects of topical lidocaine are very minimal, but include skin problems (such as irritation and redness). We are unable to recommend the use of topical lidocaine as a first‐line treatment for postherpetic neuralgia at this stage. Further studies are needed to compare topical lidocaine to other medications in the treatment of postherpetic neuralgia.
See all (11)...

Learn about...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...